Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
Active, not recruiting · NCT05881135 · Registry updated 2025-04-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET) | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 1 / Phase 2 | 2025-04-02 | NCT05881135 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Ohio State University | 297 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The Ohio State Wexner Medical Center | Columbus | United States | 3 |